Latest News

In January 2014, Dinesh Jain, CEO of Aagami a will attend J P Morgan Healthcare conference and Biotech Showcase conference respectively. Like many other thousands of executives of Life Sciences and Healthcare companies across the world, the 2 events remain an annual pilgrimage for Aagami too.

We look forward to meeting like minded professionals for exploring partnering, investments, opportunities together to further cause of the industry. Aagami acts as the much needed bridge between Global companies and emerging markets like India and Asia.

Riding high on bringing multiple successes to a client recently, Aagami looks forward to find new challenges and also represent a dozen of its esteemed clients.

Bangalore, India and Freising, Germany, December 17, 2013 

Pieris AG, a next generation therapeutic protein R&D Company, and Stelis Biopharma, a subsidiary of Bangalore-based Strides Arcolab Ltd, had entered into a long-term agreement for worldwide development and commercialisation of a protein molecule- Anticalin®, primarily focused on ophthalmology.

As per the agreement, Pieris will take care of early stages of development in each collaborative programme using a novel Anticalin-based protein, while Stelis will be responsible for advancing the molecule through a first-in-human clinical study and drug manufacturing, the company said in a statement.

The collaboration will see the merger of Pieris' innovative drug discovery and early development capabilities with Stelis' strong bio-manufacturing and clinical development expertise.

Read more...

With 2 new client wins from Europe, Aagami gears up to bring them success in their India Initiatives.

Riding high on bringing another success to a client recently, Aagami stays committed to keep bringing success to their clients

Aagami will leverage its well-structured BD team in India to handle multiple clients and be face to face with Indian prospects when needed. Aagami India team also executes Market and Business Research for clients across the world. To see the most recent success that Aagami brought to its client, please read "Pieris AG Signs Broad Co-Development Alliance for Novel Anticalin® Therapeutics with Zydus of India".

Read more...
--cMet antagonist, PRS-110, to be the flagship program--

October 16, 2013 Freising, Germany; Naperville, USA: Pieris AG, a next generation therapeutic protein R&D company and Zydus Cadila, an innovative global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare products have entered into an alliance for development and commercialization of multiple novel Anticalin®-based protein therapeutics, both companies announced today.

Read more...

We are pleased to announce that Aagami has moved to a new office located at:

Aagami, Inc.
2135 City Gate Lane, Suite 300
Naperville IL 60563
Phone: +1-630-364-1837

Below is a picture of the new office building. We are located in Suite no. 300

Aagami-New-Office-Building

Aagami CEO Mr. Dinesh Jain, is attending BIOPHARM AMERICA 2013 in Boston between 17 and 20 September 2013.

Read more...

The 2013 BIO International Convention, the global event of biotechnology, wrapped up 25 April, 2013 at McCormick Place in Chicago with a record number of partnering meetings and panel sessions on the latest science, policy issues and business opportunities and challenges facing the biotechnology industry.

Aagami had its own share in the event with 50+ partnering meetings with companies across the globe , representing more than 6 of its clients, apart from promoting its services.

Read more...

Today, a US Biotechnology company from Baton Rouge, Louisiana appointed Aagami for its out-licensing and partnering needs in India, and other emerging, high growth markets. The client company specializes in innovative cancer treatment and their mission is to improve the overall patient condition through innovative bioimmunotherapy with proven treatment protocols, to lower deaths associated with cancer and reduce the cost of cancer treatment. 

Read more...

Aagami, along with its Drug delivery technology Australian client, is on a deal making spree. After supporting deals with 3 Indians companies for this happy client, Aagami is visiting India once again in the third week of February 2013,  with likelihood to finalize another few deals along with finding strategic partners for their High End cosmetics brand.

Read more...

Aagami is glad to announce the launch of its new and redesigned website, as a new year gift to its existing and prospective clients, followers and business associates. The new site has been made future ready with the latest CMS (Content Management System) and is more user friendly, interactive, easy to navigate & social too!

Read more...

Today a Dutch biotechnology company appointed Aagami for its out-licensing and partnering needs in India. The company is building a pipeline of innovative human bispecific antibodies and single cell-derived combinations of antibodies for cancer therapy.

Read more...

A Bay area based intends to become the world\'s leading developer and supplier of antioxidant polyphenols and related innovative products for functional foods, health and dietary supplements by incorporating a Major economy of India. 

Read more...